GABA receptors remain central to anesthesia and sedation, forming the foundation for agents like propofol, etomidate, and inhalational anesthetics. While propofol remains the most widely used agent, its limitations—cardiovascular depression, contamination risk, and sudden transition to deep anesthesia drive the need for innovation. Recent research highlights “soft pharmacology” drugs, such as remimazolam and methoxycarbonyl-etomidate, which are rapidly metabolized to inactive compounds, offering precise titration and ultrashort action. These agents represent a potential paradigm shift, addressing long-standing challenges in sedation safety and control.
As methoxyflurane re-emerges in Europe for emergency analgesia, understanding receptor binding dynamics is more critical than ever. To read the full updated review and prepare for the next generation of anesthetic agents, click here . …
